Cotización TPG Real Estate Finance - TRTX-C

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

17.59

Postura de Compra

Postura de Venta

Volume Operado de la Acción

1,799

17.46 Rango del Día 17.60

0.00 Rango de 52 semanas 0.00

Precio Anterior

17.45

Precio de Apertura

17.46

Hora

100

17.59

Última hora de negociación

15:10:00

Volumen promedio (3 m)

Volumen financiero

US$ 31,616

Precio Promedio Ponderado

17.57

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease...

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and...

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride...

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE...

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml...

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer...

Amarin Reports First Quarter 2024 Business Update and Financial Results

-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24...

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
FBMSFirst Bancshares Inc	US$ 32.71 (6.79%)	14.89k
BYONBeyond Inc	US$ 14.48 (6.55%)	436.98k
STGSunlands Technology Group	US$ 8.62 (5.64%)	3.19k
MKFGMarkforged Holding Corporation	US$ 0.42 (5.58%)	638
LGF.ALions Gate Entertainment Corp	US$ 9.00 (5.14%)	18.07k
AIUMeta Data Limited	US$ 4.10 (-9.89%)	159.1k
AEVAAeva Technologies Inc	US$ 3.38 (-4.79%)	1.69k
FRGEForge Global Holdings Inc	US$ 1.4105 (-4.70%)	7.42k
RNSTRenasant Corporation	US$ 34.44 (-4.20%)	28.28k
CLVTClarivate PLC	US$ 6.60 (-3.37%)	3.89k
SWSmurfit WestRock plc	US$ 47.55 (0.00%)	4.8M
UBERUber Technologies Inc	US$ 63.79 (0.05%)	3.95M
TAT&T Inc	US$ 18.99 (0.48%)	3.89M
JCIJohnson Controls International PLC	US$ 69.30 (0.00%)	3.85M
BACBank of America Corporation	US$ 41.12 (0.07%)	2.82M